通策医疗(600763) - 2023 Q1 - 季度财报

Financial Performance - The company's Q1 2023 revenue reached ¥674,535,941.41, representing a year-on-year increase of 3.04%[4] - Net profit attributable to shareholders was ¥168,971,152.17, with a year-on-year increase of 1.49%[4] - Total operating revenue for Q1 2023 was 674,535,941.41 RMB, an increase of 3.1% compared to 654,632,302.73 RMB in Q1 2022[16] - Net profit for Q1 2023 reached 197,535,406.14 RMB, compared to 190,330,516.78 RMB in Q1 2022, marking an increase of 3.8%[17] - Earnings per share for Q1 2023 was 0.53 RMB, slightly up from 0.52 RMB in Q1 2022[17] Cash Flow - The net cash flow from operating activities was ¥156,768,252.79, showing a significant increase of 141.92% compared to the previous year[4] - Cash flow from operating activities in Q1 2023 was 615,794,420.54 RMB, compared to 583,150,305.67 RMB in Q1 2022, indicating a growth of 5.6%[17] - The net cash flow from operating activities for Q1 2023 was $156,768,252.79, an increase from $64,802,118.31 in Q1 2022, representing a growth of approximately 142.5%[18] - The cash inflow from operating activities totaled $627,885,029.71, compared to $589,571,939.02 in the same period last year, marking an increase of approximately 6.4%[18] - The company experienced a net increase in cash and cash equivalents of $332,063,079.51 in Q1 2023, contrasting with a decrease of -$109,303,293.92 in Q1 2022[19] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥5,568,084,323.16, an increase of 8.02% from the end of the previous year[5] - Current assets totaled approximately ¥1.44 billion, up from ¥1.11 billion year-over-year, indicating a growth of around 29.3%[13] - The total liabilities as of Q1 2023 amounted to 1,752,319,733.77 RMB, up from 1,536,223,702.61 RMB in the previous year, reflecting a growth of 14.1%[15] - Long-term borrowings increased significantly to 280,000,000.00 RMB from 28,800,000.00 RMB in the previous year, indicating a rise of 871.0%[15] - The total equity attributable to shareholders of the parent company was 3,479,717,992.05 RMB, compared to 3,310,746,839.97 RMB in the previous year, an increase of 5.1%[15] Operational Highlights - The number of new clinics opened under the "Dandelion" brand reached 37, contributing ¥125,780,000 in revenue, a year-on-year growth of 60%[5] - The company expects to deliver 8 new hospitals for operation in 2023[5] - The company reported a significant increase in long-term equity investments, totaling approximately ¥245.58 million, up from ¥243.07 million[14] - The company has a strong shareholder base, with the top shareholder holding approximately 33.75% of the total shares[11] Cost and Expenses - Total operating costs for Q1 2023 were 459,481,476.70 RMB, up from 436,620,005.50 RMB in Q1 2022, reflecting a rise of 5.1%[16] - Research and development expenses for Q1 2023 totaled 11,077,832.40 RMB, an increase from 10,554,549.35 RMB in Q1 2022[16] Other Financial Metrics - The weighted average return on equity decreased by 0.64 percentage points to 4.98%[4] - The company reported a significant increase in long-term borrowings by 872.22% due to new bank loans[8] - The company has not reported any significant changes in its financing or margin trading activities as of the report date[11] - There are no significant reminders or alerts regarding the company's operational status during the reporting period[12]